Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 23;21(1):1731.
doi: 10.1186/s12889-021-11776-8.

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study

Claire von Mollendorf  1   2 , Mukhchuluun Ulziibayar  3 , Bradford D Gessner  4 , Lien Anh Ha Do  5   6 , Cattram D Nguyen  5   6 , Rohini Beavon  7 , Bujinlkham Suuri  3 , Dashtseren Luvsantseren  3 , Dorj Narangerel  8 , Adam Jenney  5   9   10 , Eileen M Dunne  5   6   4 , Catherine Satzke  5   6   10 , Badarchiin Darmaa  3 , Tuya Mungun  3 , E Kim Mulholland  5   6   11
Affiliations

Evaluation of the impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia in Ulaanbaatar, Mongolia: study protocol for an observational study

Claire von Mollendorf et al. BMC Public Health. .

Abstract

Background: Community-acquired pneumonia is an important cause of morbidity and mortality in adults. Approximately one-third of pneumonia cases can be attributed to the pneumococcus. Pneumococcal conjugate vaccines (PCVs) protect against colonisation with vaccine-type serotypes. The resulting decrease in transmission of vaccine serotypes leads to large indirect effects. There are limited data from developing countries demonstrating the impact of childhood PCV immunisation on adult pneumonia. There are also insufficient data available on the burden and severity of all-cause pneumonia and respiratory syncytial virus (RSV) in adults from low resource countries. There is currently no recommendation for adult pneumococcal vaccination with either pneumococcal polysaccharide vaccine or PCVs in Mongolia. We describe the protocol developed to evaluate the association between childhood 13-valent PCV (PCV13) vaccination and trends in adult pneumonia.

Methods: PCV13 was introduced into the routine childhood immunisation schedule in Mongolia in a phased manner from 2016. In March 2019 we initiated active hospital-based surveillance for adult pneumonia, with the primary objective of evaluating trends in severe hospitalised clinical pneumonia incidence in adults 18 years and older in four districts of Ulaanbaatar. Secondary objectives include measuring the association between PCV13 introduction and trends in all clinically-defined pneumonia, radiologically-confirmed pneumonia, nasopharyngeal carriage of S. pneumoniae and pneumonia associated with RSV or influenza. Clinical questionnaires, nasopharyngeal swabs, urine samples and chest radiographs were collected from enrolled patients. Retrospective administrative and clinical data were collected for all respiratory disease-related admissions from January 2015 to February 2019.

Discussion: Establishing a robust adult surveillance system may be an important component of monitoring the indirect impact of PCVs within a country. Monitoring indirect impact of childhood PCV13 vaccination on adult pneumonia provides additional data on the full public health impact of the vaccine, which has implications for vaccine efficiency and cost-effectiveness. Adult surveillance in Mongolia will contribute to the limited evidence available on the burden of pneumococcal pneumonia among adults in low- and middle-income countries, particularly in the Asia-Pacific region. In addition, it is one of the few examples of implementing prospective, population-based pneumonia surveillance to evaluate the indirect impact of PCVs in a resource-limited setting.

Keywords: Adult pneumonia; Indirect PCV impact; Mongolia; Nasopharyngeal carriage; Pneumococcal conjugate vaccine; Streptococcus pneumoniae; Surveillance.

PubMed Disclaimer

Conflict of interest statement

BDG and RB are employees of Pfizer Inc. and provided input on the study protocol and manuscript. EMD is currently an employee of Pfizer Inc. (from August 2021), but worked for MCRI at the time that the microbiological field and laboratory protocols were developed. CvM, MU, LAHD, CDN, BS, DL, DN, AJ, CS, BD, TM and EKM are investigators on this collaborative research project funded by Pfizer.

Figures

Fig. 1
Fig. 1
Schematic diagram of study design and timelines
See this image and copyright information in PMC

References

    1. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Team AAPBS. Andreo F, Beovic B, Blanco S, Boersma WG, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273. doi: 10.1371/journal.pone.0060273. - DOI - PMC - PubMed
    1. Song JY, Eun BW, Nahm MH. Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward. Infect Chemother. 2013;45(4):351–366. doi: 10.3947/ic.2013.45.4.351. - DOI - PMC - PubMed
    1. Kalina WV, Souza V, Wu K, Giardina P, McKeen A, Jiang Q, Tan C, French R, Ren Y, Belanger K, McElhiney S, Unnithan M, Cheng H, Mininni T, Giordano-Schmidt D, Gessner BD, Jansen KU, Pride MW. Qualification and clinical validation of an immunodiagnostic assay for detecting 11 additional Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Infect Dis. 2020;71(9):e430–e438. doi: 10.1093/cid/ciaa158. - DOI - PMC - PubMed
    1. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, French R, Callahan J, Webber C, Gruber WC, Bonten MJM, Jansen KU. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol. 2012;19(8):1131–1141. doi: 10.1128/CVI.00064-12. - DOI - PMC - PubMed
    1. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, Pneumococcal Carriage G. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–855. doi: 10.1586/erv.12.53. - DOI - PubMed

Publication types

MeSH terms